Bridge Biotherapeutics, Inc.

KOSDAQ:A288330 Stock Report

Market Cap: ₩155.0b

Bridge Biotherapeutics Valuation

Is A288330 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A288330 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A288330's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A288330?

Key metric: As A288330 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A288330. This is calculated by dividing A288330's market cap by their current book value.
What is A288330's PB Ratio?
PB Ratio15.4x
Book₩9.87b
Market Cap₩155.01b

Price to Book Ratio vs Peers

How does A288330's PB Ratio compare to its peers?

The above table shows the PB ratio for A288330 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
A048530 iNtRON Biotechnology
2xn/a₩188.5b
A084650 LabGenomics
0.9xn/a₩200.8b
A299660 Cellid
3.9xn/a₩135.1b
A095700 Genexine
0.9xn/a₩258.3b
A288330 Bridge Biotherapeutics
15.4xn/a₩155.0b

Price-To-Book vs Peers: A288330 is expensive based on its Price-To-Book Ratio (15.4x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does A288330's PB Ratio compare vs other companies in the KR Biotechs Industry?

2 CompaniesPrice / BookEstimated GrowthMarket Cap
A377740 BioNote
0.3xn/aUS$342.48m
A109960 AP Healthcare
0.3xn/aUS$69.81m
No more companies available in this PB range
A288330 15.4xIndustry Avg. 2.5xNo. of Companies11PB01.63.24.86.48+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: A288330 is expensive based on its Price-To-Book Ratio (15.4x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A288330's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A288330 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio15.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A288330's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hanmi Pharm

₩3.6t

A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.

A128940

₩278,000.00

7D

-4.0%

1Y

-6.4%

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,270.00

7D

-2.5%

1Y

n/a

Medy-Tox

₩856.2b

Operates as a biopharmaceutical company in South Korea.

A086900

₩127,200.00

7D

1.0%

1Y

-42.2%